Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Department of Cardiovascular Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Cell Prolif. 2024 Aug;57(8):e13636. doi: 10.1111/cpr.13636. Epub 2024 Mar 19.
Cardiovascular disease (CVD) is a group of diseases that primarily affect the heart or blood vessels, with high disability and mortality rates, posing a serious threat to human health. The causative factors, pathogenesis, and characteristics of common CVD differ, but they all involve common pathological processes such as inflammation, oxidative stress, and fibrosis. S100A9 belongs to the S100 family of calcium-binding proteins, which are mainly secreted by myeloid cells and bind to the Toll-like receptor 4 and receptor for advanced glycation end products and is involved in regulating pathological processes such as inflammatory response, fibrosis, vascular calcification, and endothelial barrier function in CVD. The latest research has found that S100A9 is a key biomarker for diagnosing and predicting various CVD. Therefore, this article reviews the latest research progress on the diagnostic and predictive, and therapeutic value of S100A9 in inflammatory-related CVD such as atherosclerosis, myocardial infarction, and arterial aneurysm and summarizes its molecular mechanisms in the progression of CVD, aiming to explore new predictive methods and to identify potential intervention targets for CVD in clinical practice.
心血管疾病（CVD）是一组主要影响心脏或血管的疾病，其具有高残疾率和死亡率，对人类健康构成严重威胁。常见 CVD 的致病因素、发病机制和特征不同，但它们都涉及炎症、氧化应激和纤维化等共同的病理过程。S100A9 属于钙结合蛋白 S100 家族，主要由髓样细胞分泌，与 Toll 样受体 4 和晚期糖基化终产物受体结合，参与调节炎症反应、纤维化、血管钙化和内皮屏障功能等病理过程在 CVD 中。最新研究发现，S100A9 是诊断和预测各种 CVD 的关键生物标志物。因此，本文综述了 S100A9 在动脉粥样硬化、心肌梗死和动脉瘤等炎症相关 CVD 中的诊断和预测及治疗价值的最新研究进展，并总结了其在 CVD 进展中的分子机制，旨在探索新的预测方法，为临床实践中 CVD 的潜在干预靶点提供依据。
